FINWIRES · TerminalLIVE
FINWIRES

Neurizon Therapeutics Secures NIH Grant to Support Investigational ALS Treatment; Shares Up 31%

By

Neurizon Therapeutics (ASX:NUZ) said the US National Institutes of Health (NIH) has awarded a multimillion-dollar, multi-year grant to support an expanded access protocol (EAP) for its investigational amyotrophic lateral sclerosis (ALS) therapy NUZ-001, according to a Wednesday filing with the Australian bourse.

The program is expected to provide up to 200 ALS patients who are ineligible for clinical trials with access to NUZ-001 for up to 96 weeks, alongside the ongoing phase two and three Healey ALS platform trial, per the filing.

The company will serve as the regulatory sponsor and provide the drug, while the Healey and AMG Center for ALS will oversee clinical operations, the filing said.

The EAP is fully funded by the NIH and is expected to involve about 20 clinical sites across the US, alongside a national virtual site, with enrolment targeted to begin in the first quarter of 2027, subject to regulatory and operational approvals, the filing added.

The company's shares jumped 31% in recent Wednesday trade.

Related Articles

Asia

Majestic Dragon Aerotech Appoints Marketing Chief

Majestic Dragon Aerotech (HKG:0918) has appointed Zhang Chen as the company's chief marketing officer, according to a Monday bourse filing.Zhang has over 10 years of experience in real estate development and in managing hotel operations and fire safety systems. His appointment will be effective Dec. 7.

HKG:0918
Asia

HRnetGroup Gets SGX-ST Preliminary Nod for Share Listing

HRnetGroup (SGX:CHZ) has received in-principle approval from the Singapore Exchange Securities Trading (SGX-ST) for the listing and quotation of 241,527 shares to be transferred to certain employees and executive director.The approval is subject to the company complying with SGX-ST listing requirements, including obtaining specific shareholders' approval where applicable, according to a Monday Singapore Exchange filing.The company will make the necessary announcement once the shares are transferred.

SGX:CHZ
Asia

Sequoia Financial Group Ex-Boss Faces 10-Year ASIC Ban From Financial Services Roles

Sequoia Financial Group (ASX:SEQ) former Chief Executive Garry Crole has been banned by the Australian Securities and Investments Commission (ASIC) for 10 years from performing any function involved in carrying on a financial services business as a director or responsible manager, according to a Tuesday statement by ASIC.The regulator said Crole failed to adequately respond to serious concerns about the financial advice model used by former Interprac-authorized representatives, who advised thousands of clients to invest superannuation in the now-collapsed First Guardian and Shield Master Funds.The company did not immediately respond to anemail request for comment.

ASX:SEQ